Ibrutinib Plus Rituximab Elicits High Responses in Indolent Mantle Cell Lymphoma
16457
post-template-default,single,single-post,postid-16457,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Ibrutinib Plus Rituximab Elicits High Responses in Indolent Mantle Cell Lymphoma

Ibrutinib Plus Rituximab Elicits High Responses in Indolent Mantle Cell Lymphoma

Indolent MCL patients treated with frontline ibrutinib plus rituximab showed an overall response of 84% after 12 cycles of treatment, with 80% of patients experiencing a CR. Undetectable MRD in the peripheral blood was achieved in 87% of patients. The estimated PFS at 36 months was 93%. At 2 years, 69% of patients could discontinue ibrutinib because of undetectable MRD. (Ref: Giné E et al. J Clin Oncol. 2022)
#oncologyresearch

https://www.linkedin.com/feed/update/urn:li:activity:6921011455219646464

No Comments

Sorry, the comment form is closed at this time.